Navigation Links
MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting

ess of blast percentage, cytogenetics, or age, responses were observed in all risk groups. Additionally, the survival of the Dacogen treated group compared favorably to that of 330 patients with AML (over 60 years of age) given standard induction therapy containing cytarabine and treated in the same time-period. Non-hematologic adverse events included myocardial infarction, dyspnea, hyperbilirubinemia, dehydration, syncope, headache, and hypokalemia.

Phase 1 Study of Dacogen in Patients with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Interim results of two consecutive phase 1 studies designed to evaluate the dose, toxicity, biologic response, and preliminary clinical response of Dacogen alone and in combination with hyperCVAD, in patients with relapsed/refractory ALL were presented on Saturday, June 2, 2007. Patients were treated with intravenous Dacogen administered daily for five days every other week (starting at 100

mg/m2 per course) with 7 of 13 patients subsequently retreated with Dacogen (starting at 25 mg/m2 per course) and given hyperCVAD every three to four weeks. Both agents were started on Day 1. Two patients had complete bone marrow response on Dacogen alone with one of these patients also having a complete response except for platelets (CRp) with subsequent hyperCVAD therapy. Two additional patients who also received combination therapy had a complete response (CR). One of the responding patients received a successful allogeneic stem cell transplant. Correlative studies on patient peripheral blood samples demonstrated hypomethylation and hematological control. No significant Grade 3 or Grade 4 drug related non-hematological toxicities were observed.

Gliadel(R) Wafer

Retrospective Data on the Overall Survival of Patients with Glioblastoma Treated with Gliadel Wafer Implantation as Part of Multimodal Therapy

The results of a retrospective analysis to assess the survival of patients treated with rotat
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:9/30/2014)... 30, 2014  Tasly Pharmaceuticals, Inc., the world,s ... announced today the launch of Deepure. ... address men and women concerned with supporting their ... old age while helping keep their health care ... and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, ...
(Date:9/30/2014)...  Decision Resources Group finds that the markets for ... , Russia , India ... will see robust expansion as these economies expand and ... Although revenues will be somewhat impeded by poor distribution ... times and demand for low-cost products, the market will ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, ... pre-clinical studies that,provide evidence for chemotherapy ... (ABRAXANE(R) for Injectable,Suspension (paclitaxel protein-bound particles ... drugs like,bevacizumab (Avastin(R)) at the 98th ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... results from two pre-clinical studies that,support the ... rich in,cysteine) expression in cancer and Abraxis' ... Association for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:9/30/2014)... SILVERTHORNE, CO September 30, 2014 Keystone Symposia ... and the first in its 2014-15 Global Health Series ... at the Sheraton Seattle Hotel immediately following the ... grantees. The four-day conference is part of the Keystone ... Melinda Gates Foundation, which has also funded travel awards ...
(Date:9/30/2014)... September 30, 2014 A new study ... University studied the impact of stress on metabolism after eating ... french fries from a fast food restaurant, about 930 calories ... metabolism for 20 minutes every hour for 7 hours, conducting ... that women who had experienced a stressful event in their ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s leader ... specialty practice through a unique partnership with an established ... within the company’s Shrewsbury location and will be staffed ... American Heart Center, P.C., a highly regarded practice located ... Medicine Alliance patients top notch cardiovascular care without leaving ...
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2
... , , ... BZ and APAR < GO >; Reuters: AMIL3.SA), the largest ... released on,November 19, 2009 and December 2, 2009, informs its ... Public Offer defined below,were started today, having as Applicant its ...
... Dec. 9 AdCare Health Systems, Inc. (NYSE AMEX: ... and management company, today reported that it completed a private ... million in cash to fund the Company,s growth initiatives, which ... as well as new management contracts. , "We are pleased ...
... Patients who experience dermatologic toxic effects from epidermal growth ... skin and nail infections, according to a new study ... the National Cancer Institute . This new class ... cancers including lung, pancreatic, breast, head and neck, and ...
... record amounts of money for such efforts , WEDNESDAY, ... tobacco prevention programs by more than 15 percent in ... of money from tobacco taxes and from the 1998 ... "Fully funded tobacco prevention and cessation programs stop addiction ...
... ... non-biased assistance to Medicare eligibles in finding the right Medicare plan for their particular ... ... officially beginning on November 15th. 6,000 people become eligible for Medicare everyday in the ...
... , , , DETROIT, Dec. 9 ... of the 26th Annual Awards. , On September 29 at ... 26th Annual Awards Ceremony. The theme for this ... , These awards were presented to corporations and individuals who ...
Cached Medicine News:Health News:AdCare Health Systems Completes Private Placement to Fund Aggressive Growth Initiatives 2Health News:AdCare Health Systems Completes Private Placement to Fund Aggressive Growth Initiatives 3Health News:States Slash Funding for Tobacco Prevention Programs 2Health News:States Slash Funding for Tobacco Prevention Programs 3Health News:www.RightMedicare.com Launches to Offer Non-Biased Medicare Enrollment Assistance 2Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... you can enjoy the ... of the most technically ... gloves on the market. ... provide the needed barrier ...
... The Siegel MAST Intraoperative Leg Positioner frees the ... the need for 2nd assistants to hold the ... on the procedure instead of leg positioning. The ... place the leg in any position required for ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,475-5) ...
Medicine Products: